About: Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	In a recent issue of this journal, Kalla et al (1) reported that 4-aminopyridine (4-AP) alleviates the symptoms of downbeat nystagmus (DBN) significantly more than 3,4-diaminopyridine (3,4-DAP). Both drugs are potassium-channel blockers, but 4-aminopyridine is lipid-soluble and more easily crosses the blood-brain-barrier. 3,4-diaminopyridine is not lipid soluble, with direct effects in the peripheral nervous system and indirect effects in the central nervous system via its metabolites (1,2). In the report by Kalla et al (1), 1 male patient suffered from bilateral vestibular failure (disorder of the peripheral nervous system) as well as DBN (disorder of the central nervous system). We now document this case in detail. At the time of the study, the patient was 58 years old. Ten years earlier, he had traveled to Indonesia, where he suffered from extreme diarrhea with severe weight loss, followed by the development of tinnitus, oscillopsia, postural instability, and bilateral vestibular failure. MRI of the brain was normal. On examination, he was found to have DBN, which was documented with electronystagmography. The patient showed improvement of DBN following the administration of 3,4-DAP but not with 4-AP. In a recent issue of this journal, Kalla et al (1) reported that 4-aminopyridine (4-AP) alleviates the symptoms of downbeat nystagmus (DBN) significantly more than 3,4-diaminopyridine (3,4-DAP). Both drugs are potassium-channel blockers, but 4-aminopyridine is lipid-soluble and more easily crosses the blood-brain-barrier. 3,4-diaminopyridine is not lipid soluble, with direct effects in the peripheral nervous system and indirect effects in the central nervous system via its metabolites (1,2). In the report by Kalla et al (1), 1 male patient suffered from bilateral vestibular failure (disorder of the peripheral nervous system) as well as DBN (disorder of the central nervous system). We now document this case in detail. At the time of the study, the patient was 58 years old. Ten years earlier, he had traveled to Indonesia, where he suffered from extreme diarrhea with severe weight loss, followed by the development of tinnitus, oscillopsia, postural instability, and bilateral vestibular failure. MRI of the brain was normal. On examination, he was found to have DBN, which was documented with electronystagmography. The patient showed improvement of DBN following the administration of 3,4-DAP but not with 4-AP. (en)
Title	Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus (en)
skos:prefLabel	Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus (en)
skos:notation	RIV/00064173:_____/12:43896082!RIV13-MZ0-00064173
http://linked.open...avai/predkladatel	Fakultní nemocnice Královské Vinohrady
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Hahn, A.
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Královské Vinohrady
http://linked.open...dnocenehoVysledku	121832
http://linked.open...ai/riv/idVysledku	RIV/00064173:_____/12:43896082
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Treatment; Aminopyridine (en)
http://linked.open.../riv/klicoveSlovo	Aminopyridine Treatment
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[EF3B3C05A67A]
http://linked.open...i/riv/nazevZdroje	Journal of Neuro-Ophthalmology
http://linked.open...in/vavai/riv/obor	FF
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	12 (xsd:int)
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	32
http://linked.open...iv/tvurceVysledku	Hahn, Aleš
http://linked.open...ain/vavai/riv/wos	000304790500019
issn	1070-8022
number of pages	1 (xsd:int)
http://bibframe.org/vocab/doi	10.1097/WNO.0b013e31824f397f
is http://linked.open...avai/riv/vysledek of	Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software